


KY-556

Cat. No.:	HY-U00148
CAS No.:	110816-78-9
Molecular Formula:	C ₃₃ H ₃₈ Cl ₂ N ₂ O ₁₂
Molecular Weight:	725.57
Target:	Others
Pathway:	Others
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 83.33 mg/mL (114.85 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	1.3782 mL	6.8911 mL	13.7823 mL	
5 mM	0.2756 mL	1.3782 mL	2.7565 mL	
10 mM	0.1378 mL	0.6891 mL	1.3782 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

KY-556 is a promising and orally-active pro-agent of disodium cromoglycate (DSCG) against allergic diseases.

In Vivo

The oral anti-allergic effect of KY-556 (N-556) is investigated. N-556 (10-100 mg/kg, p.o.) inhibits dose-dependently the 48-hr homologous passive cutaneous anaphylaxis (PCA) in rats, and the duration of action is longer than that of intravenous Disodium cromoglycate (DSCG). N-556 (20 and 100 mg/kg once a day for 20 consecutive days, p.o.) tends to inhibit the histamine release from actively sensitized rat lung fragments. N-556 (100 mg/kg, p.o.) shows the prolongation of survival time in the rat systemic anaphylaxis. N-556 (100 mg/kg, p.o.) significantly inhibits the increased airway resistance in experimental asthma in rats^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Ethnopharmacol. 2023 Jan 2;305:116093.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Nakamura S, et al. Effects of N-556 on experimental allergy models in rats. *Arerugi*. 1990 Dec;39(12):1621-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA